Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Argus Health
Farmers Insurance
Daiichi Sankyo
Moodys
Deloitte
Fuji
Fish and Richardson
Covington

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,940,786

« Back to Dashboard

Which drugs does patent 8,940,786 protect, and when does it expire?

Patent 8,940,786 protects DOCETAXEL and is included in one NDA.

This patent has sixteen patent family members in sixteen countries.
Summary for Patent: 8,940,786
Title:Non-aqueous taxane nanodispersion formulations and methods of using the same
Abstract: Non-aqueous, ethanol-free taxane nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include a taxane, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid component, wherein the organic acid component is soluble in the non-aqueous solvent and the amount by weight of non-ionic surfactant is equal to or greater than the amount by weight of non-aqueous solvent. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations. Non-aqueous, ethanol-free docetaxel nanodispersion formulations are provided. Nanodispersion formulations of embodiments of the invention include docetaxel, an oil, a non-ionic surfactant, a non-aqueous solvent, and an organic acid which is soluble in the non-aqueous solvent and is substantially free of any conjugate base. Also provided are methods of using the nanodispersion formulations, as well as kits that include the nanodispersion formulations.
Inventor(s): Nabeta; Kiichiro (Tokyo, JP)
Assignee: Teikoku Pharma USA, Inc. (San Jose, CA)
Application Number:14/041,675
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Device;

Drugs Protected by US Patent 8,940,786

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eagle Pharms DOCETAXEL docetaxel SOLUTION;IV (INFUSION) 205934-001 Dec 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION ➤ Sign Up
Eagle Pharms DOCETAXEL docetaxel SOLUTION;IV (INFUSION) 205934-002 Dec 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION ➤ Sign Up
Eagle Pharms DOCETAXEL docetaxel SOLUTION;IV (INFUSION) 205934-003 Dec 22, 2015 RX No No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,940,786

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,308,195 Non-aqueous taxane formulations and methods of using the same ➤ Sign Up
9,763,880 Non-aqueous taxane formulations and methods of using the same ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Argus Health
Harvard Business School
Farmers Insurance
Accenture
Healthtrust
Teva
Mallinckrodt
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.